The company is distinguished by the application of it’s Haptenix© technology platform.  Haptenization,  a pioneering technique developed from the work of Nobel laureate Dr. Karl Landsteiner, is a process that uses chemicals called ‘haptens’ to train the immune system to recognize and aggressively target tumor or viral proteins, thus enhancing  T cell response against both tumor and viral antigens. This is critical, as T-cells target and destroy viral or cancerous cells.  The Haptenix© platform technology is the foundation of BVX-0918, the Company’s Phase I vaccine candidate for Stage III/Stage IV ovarian cancer.